IMMIX BIOPHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.17 USD | +2.36% |
|
-5.65% | -68.64% |
| 04-29 | Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment | MT |
| 04-18 | Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 57.3M 78.85M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M -28.9M | Net income 2025 * | -23M -31.65M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 11.99M 16.5M | Net Debt 2025 * | 14.6M 20.09M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.33
x | P/E ratio 2025 * |
-2.3
x | Employees | 16 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.94% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.36% | ||
| 1 week | -5.65% | ||
| 1 month | -29.32% | ||
| 3 months | -43.19% | ||
| 6 months | -40.06% | ||
| Current year | -68.64% |
1 week
2.02
2.40
1 month
1.943.13
Current year
1.946.88
1 year
1.407.75
3 years
0.688.68
5 years
0.688.68
10 years
0.688.68
| Managers | Title | Age | Since |
|---|---|---|---|
Ilya Rachman
CEO | Chief Executive Officer | 52 | 11-12-31 |
Gabriel Morris
DFI | Director of Finance/CFO | 38 | 21-02-28 |
Graham Ross
CTO | Chief Tech/Sci/R&D Officer | 64 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jane Buchan
BRD | Director/Board Member | 60 | 21-06-30 |
Jason Hsu
BRD | Director/Board Member | 50 | 12-12-31 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 2.17 | +2.36% | 107,287 |
| 24-04-29 | 2.12 | -0.47% | 227,470 |
| 24-04-26 | 2.13 | +1.43% | 84,843 |
| 24-04-25 | 2.1 | -1.41% | 83,185 |
| 24-04-24 | 2.13 | -7.39% | 59,783 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm
More quotes
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Sector
Pharmaceuticals
Calendar
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.17
USD
Average target price
14
USD
Spread / Average Target
+545.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -68.64% | 57.28M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.98% | 31.28B | |
| +57.86% | 25.27B | |
| -16.24% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- IMMX Stock
